Nivolumab for small cell lung cancer in combination with ipilimumab – first line maintenance therapy

February 2017
Technology Description:

Nivolumab and ipilimumab is a new drug combination to treat small cell lung cancer after it has first been treated with chemotherapy. Small cell lung cancer is a fast growing type of lung cancer which is usually caused by smoking. Both nivolumab and ipilimumab are given straight into the bloodstream and stimulate the body’s immune system to fight the cancer cells.